Compare GEMI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEMI | ALLO |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | 650 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.3M | 539.4M |
| IPO Year | N/A | 2018 |
| Metric | GEMI | ALLO |
|---|---|---|
| Price | $5.17 | $2.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $8.31 | ★ $8.35 |
| AVG Volume (30 Days) | 1.5M | ★ 15.1M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.05 | N/A |
| Revenue Next Year | $39.56 | $142,416.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.91 | $0.86 |
| 52 Week High | $34.67 | $4.46 |
| Indicator | GEMI | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 48.95 |
| Support Level | $4.01 | $2.12 |
| Resistance Level | $5.24 | $2.67 |
| Average True Range (ATR) | 0.32 | 0.13 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 86.69 | 48.81 |
Gemini Space Station Inc is engaged on unlocking the next era of financial, creative, and personal freedom. It envisions a future where crypto will redesign the global financial system, the internet, and money in a way that provides greater choice, independence, and opportunity for all. As a trusted bridge between the traditional financial system and the emerging crypto economy, It is providing access for individuals and institutions to a decentralized future that is more open, fair, and secure. Its core exchange product has expanded over time to become a comprehensive platform for its users to engage with the crypto economy, including a derivatives exchange, staking services, an over-the-counter (OTC) trading desk, institutional-grade custody, and others.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.